Eton Pharmaceuticals, Inc.

ETON Nasdaq CIK: 0001710340

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 21925 W. FIELD PARKWAY, DEER PARK, IL, 60010-7278
Mailing Address 21925 W. FIELD PARKWAY, DEER PARK, IL, 60010-7278
Phone (847) 787-7361
Fiscal Year End 1231
EIN 371858472

Financial Overview

FY2025

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
10-K Annual financial report March 19, 2026 View on SEC
8-K Current report of material events March 19, 2026 View on SEC
8-K Current report of material events March 2, 2026 View on SEC
8-K Current report of material events February 25, 2026 View on SEC
4 Insider stock transaction report February 5, 2026 View on SEC
8-K Current report of material events February 2, 2026 View on SEC
4 Insider stock transaction report January 14, 2026 View on SEC
4 Insider stock transaction report January 14, 2026 View on SEC
4 Insider stock transaction report January 14, 2026 View on SEC

Annual Reports

10-K March 19, 2026
  • Acquisition of Increlex® (Dec 2024) provides immediate, steady income and expands market reach for 2025.
  • Successful launch of multiple specialized products (PKU GOLIKE, Selenix DS200, Galzin) in 2024.
View Analysis

Material Events

8-K Acquisition March 2, 2026
High Impact
  • Immediate revenue and profit growth from an established, FDA-approved product.
  • Strategic expansion into specialized pharmaceutical markets with an Orphan Drug designated product.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.